跳至主要内容
临床试验/NCT04140838
NCT04140838已完成不适用

Cost-utility and Physiological Effects of Acceptance and Commitment Therapy and Behavior Activation in Patients With Chronic Pain and Comorbid Major Depression (IMPACT Project)

Fundació Sant Joan de Déu2 个研究点 分布在 1 个国家目标入组 234 人开始时间: 2020年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
234
试验地点
2
主要终点
Aggregate score of the Physical Function, Body Pain and Vitality subscales of the SF-36

研究概览

简要总结

Objectives: (1) To analyze the effectiveness of adding a group-based form of Acceptance and Commitment Therapy (ACT) or a behavioural activation program for depression (TACD) to the treatment as usual (TAU) for patients diagnosed of chronic pain and comorbid mild-moderate major depression; (2) To examine the cost-utility of these psychological treatments from healthcare and societal perspectives; (3) To measure a set of biomarkers alongside the RCT in order to know the physiological underpinnings of these psychological therapies and to identify potential predictors of treatment response.

Methodology: 12-month multisite, randomised, controlled trial (RCT) Centres: Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat) and Hospital del Mar (Barcelona).

Participants. 225 adult patients with chronic pain that meet the diagnostic criteria for mild-moderate major depression will be randomly assigned to one of the three study arms: TAU + ACT vs. TAU + TACD vs. TAU.

Primary outcome: Quality of life. Secondary outcomes: pain intensity, depression severity, anxiety symptoms, pain catastrophising, and pain acceptance. Costs to the healthcare system and to society and quality adjusted life years (QALYs). In addition, the empirically validated app Multicenter Pain Monitor® will be used to monitor participants alongside the treatments (ecological momentary assessment). Biomarkers: hair cortisol and cortisone, corticosteroid-binding globulin (CBG), ACTH and cortisol in plasma, and genotyping of 5 polymorphisms in the FKBP5 gene involved in the regulation of the hypothalamic-pituitary-adrenal axis activity, cytokines, Th1: IL-6, IL-8, TNF-α; cytokines Th2: IL-10 + hsCRP test, and vitamin D levels. Main statistical analyses: Intention-to-Treat analyses that will include all participants who undergo random allocation, using multiple imputation to replace missing values. Linear mixed-effects models will be performed using Restricted Maximum Likelihood to estimate the parameters. Calculation of between-groups effect sizes using Cohen's d and of the number-needed-to-treat. Economic evaluation: cost-utility ratios evaluated by applying bootstrapping techniques, acceptability curves, and sensitivity analyses.

详细描述

The IMPACT Project's main objective is to determine the effectiveness of adding to the standard care of patients with chronic pain and mild to moderate major depression a group programme based on ACT or a group programme based on BATD and analyse the cost-utility of these psychological treatments from a health and social perspective. Likewise, both in chronic pain and in other usually associated psychiatric diseases, there is a ubiquitous lack of knowledge about what specific psychological and physiological mechanisms are modified by these third generation psychotherapies and how they relate to the observed clinical results. The potential predictors of response to these treatments are also unknown. In chronic musculoskeletal pain where central sensitization plays an important role, alterations have been found in different markers associated with an increased experience of pain. Some of these alterations in markers (e.g. high levels of pro-inflammatory cytokines) would also appear to be shared with other psychiatric diseases (major depression), a fact that would suggest a possible common mechanism involved in the etiopathogenesis of these diseases. Third generation psychotherapies have proven effective for pain management and regulation of the immune response. The IMPACT Multicentre Project (Improving Pain and Depression with ACT and BATD) will significantly expand the limited knowledge available about how ACT and BATD therapies exert their effects on relevant clinical improvement variables and will try to identify response predictive factors to these treatments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients who have been visited in the last 3 years in the participating centres and who have been given a diagnosis of chronic non-cancer musculoskeletal pain. In telephone screening, it will be evaluated whether the current pain intensity is at least moderate and PHQ-9 will be administered to confirm the presence of mild to moderate active depression.
  • •Patients between 18 and 70 years of age.
  • •Diagnosis of chronic pain (≥ 3 months) according to medical history (current pain ≥ 4 out of 10)
  • •Diagnosis of mild to moderate depression according to PHQ-9 (score between 5 and 19).
  • •Understanding of Spanish.
  • •Access to a Smartphone (with Android operating system).
  • •Written informed consent.

排除标准

  • •Presence of cognitive impairment according to MMSE (≤ 24 out of 30).
  • •Previous (last year) or current psychological treatment.
  • •Presence of severe mental disorder (e.g. psychotic disorder) related to substance dependence/abuse or another disease that affects the CNS (organic brain pathology or head trauma of any severity).
  • •Presence of serious, uncontrolled or degenerative medical disease that may interfere with affective symptoms.
  • •Risk of suicide (Item 9 score of PHQ-9 ≥ 2).
  • •Patients involved in legal proceedings with employers in relation to their illness.
  • •Patients with scheduled surgical intervention or other interventions.
  • •Inability to attend group treatment sessions.
  • •Additional exclusion criteria for the study of biomarkers (50% of subjects in each branch):
  • •Cold/infection symptoms on the day of blood collection.
  • •Needle phobia.
  • •BMI > 36 kg/m2 or weight > 110 kg
  • •Consumption > 8 units of caffeine per day (maximum 1 drink with caffeine on the day of testing).
  • •Smoker > 5 cigarettes a day.
  • •Being pregnant or breastfeeding

研究组 & 干预措施

TAU + Acceptance and Commitment Therapy (ACT)

Experimental

This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.

干预措施: Acceptance and Commitment Therapy (ACT) (Behavioral)

TAU + Behavioral Activation Therapy for Depression (BATD)

Experimental

Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context.

干预措施: Behavioral Activation Therapy for Depression (BATD) (Behavioral)

Treatment as Usual (TAU)

Active Comparator

Standard Care. Although there is no treatment considered as the gold standard for chronic pain and comorbid major depression, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.

干预措施: Treatment as Usual (TAU) (Other)

TAU + Behavioral Activation Therapy for Depression (BATD)

Experimental

Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context.

干预措施: Treatment as Usual (TAU) (Other)

TAU + Acceptance and Commitment Therapy (ACT)

Experimental

This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.

干预措施: Treatment as Usual (TAU) (Other)

结局指标

主要结局

Aggregate score of the Physical Function, Body Pain and Vitality subscales of the SF-36

时间窗: Through study completion, an average of 1 year

The range of scores is 15 to 65. Higher scores indicate better quality of life.

次要结局

  • Hospital Anxiety and Depression Scale (HADS)(Through study completion, an average of 1 year.)
  • Numerical pain scale(Through study completion, an average of 1 year)
  • Pain Catastrophising Scale (PCS)(Through study completion, an average of 1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Juan Vicente Luciano

Principal Investigator

Fundació Sant Joan de Déu

研究点 (2)

Loading locations...

相似试验